Fibrolamellar Carcinoma disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

FHCC MCID: FBR086 MIFTS: 61	Fibrolamellar Carcinoma (FHCC) Categories: Cancer diseases, Gastrointestinal diseases, Liver diseases, Rare diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs Expand all tables

Sources

Aliases & Classifications for Fibrolamellar Carcinoma

MalaCards integrated aliases for Fibrolamellar Carcinoma:

Name: Fibrolamellar Carcinoma ¹² ⁵² ¹⁵ ¹⁷

Fibrolamellar Hepatocellular Carcinoma ¹² ⁵² ⁵⁸ ⁴³ ⁷¹

Fibrolamellar Hepatocarcinoma ⁵² ⁵⁸

Fhcc ⁵² ⁵⁸

Eosinophilic Hepatocellular Carcinoma with Lamellar Fibrosis ⁵²

Polygonal Cell Hepatocellular Carcinoma with Fibrous Stroma ⁵²

Hepatocellular Carcinoma with Increased Stromal Fibrosis ⁵²

Hepatocellular Carcinoma, Fibrolamellar ¹²

Eosinophilic Glassy Cell Hepatoma ⁵²

Fibrolamellar Oncocytic Hepatoma ⁵²

Oncocytic Hepatocellular Tumor ¹²

Fl-Hcc ⁵²

Characteristics:

Orphanet epidemiological data:

⁵⁸

fibrolamellar hepatocellular carcinoma
Inheritance: Not applicable; Prevalence: <1/1000000 (United States); Age of onset: Adolescent,Adult;

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Liver diseases Gastrointestinal diseases

See all MalaCards categories (disease lists)

ICD10: ³³

Neoplasms

Malignant neoplasms of digestive organs

Malignant neoplasm of liver and intrahepatic bile ducts

Malignant neoplasm: Liver cell carcinoma

Orphanet: ⁵⁸

Rare hepatic diseases

External Ids:

Disease Ontology ¹² DOID:5015

MeSH ⁴³ C537258

NCIt ⁴⁹ C4131

SNOMED-CT ⁶⁷ 15619004 253018005

ICD10 via Orphanet ³³ C22.0

UMLS via Orphanet ⁷² C0334287

Orphanet ⁵⁸ ORPHA401920

EFO ¹⁷ EFO_1000256

UMLS ⁷¹ C0334287

Sources

Summaries for Fibrolamellar Carcinoma

NIH Rare Diseases : ⁵² Fibrolamellar carcinoma (FLC) is a rare form of liver cancer which is generally diagnosed in adolescents and young adults (before age 40). Many people with early FLC have no signs or symptoms of the condition. When present, symptoms are often nonspecific (i.e. abdominal pain, weight loss, malaise ) and blamed on other, more common conditions. The exact underlying cause of FLC is poorly understood. Unlike other forms of liver cancer, FLC typically occurs in the absence of underlying liver inflammation or scarring; thus, specific risk factors for this condition remain unidentified. FLC is typically treated with surgical resection .

MalaCards based summary : Fibrolamellar Carcinoma, also known as fibrolamellar hepatocellular carcinoma, is related to mixed fibrolamellar hepatocellular carcinoma and intrahepatic cholangiocarcinoma, and has symptoms including fever, abdominal pain and icterus. An important gene associated with Fibrolamellar Carcinoma is PRKACA (Protein Kinase CAMP-Activated Catalytic Subunit Alpha), and among its related pathways/superpathways are Developmental Biology and PI3K-Akt signaling pathway. The drugs Everolimus and Letrozole have been mentioned in the context of this disorder. Affiliated tissues include liver, lymph node and bone marrow, and related phenotypes are Decreased shRNA abundance (Z-score < -2) and Decreased shRNA abundance (Z-score < -2)

Disease Ontology : ¹² A hepatocellular carcinoma characterized microscopically by laminated fibrous layers interspersed between the tumour cells. The polygonal, deeply eosinophilic tumor cells arise in non-cirrhotic livers.

Wikipedia : ⁷⁴ Fibrolamellar hepatocellular carcinoma (FHCC) is a rare form of hepatocellular carcinoma (HCC) that... more...

Sources

Related Diseases for Fibrolamellar Carcinoma

Diseases related to Fibrolamellar Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 251)

#	Related Disease	Score	Top Affiliating Genes
1	mixed fibrolamellar hepatocellular carcinoma	32.7	PRKACA KRT7 KRT19 DNAJB1
2	intrahepatic cholangiocarcinoma	31.1	KRT7 KRT19 FGFR2 AFP
3	pancreatoblastoma	30.8	SYP NTS AFP
4	cholangiocarcinoma	30.6	KRT8 KRT7 KRT19 FGFR2 CCKBR AFP
5	cholangitis, primary sclerosing	30.5	NR0B2 KRT7 KRT19 AFP
6	sclerosing hepatic carcinoma	30.5	KRT19 AFP
7	pancreatic cancer	29.3	NTS MIR375 KRT8 KRT7 KRT19 GAST
8	ovary neuroendocrine neoplasm	10.7	SYP KRT7
9	fgfr craniosynostosis syndromes	10.6	FGFR2 FGFR1
10	mucinous adenofibroma	10.6	SYP KRT7
11	hepatocellular carcinoma	10.6
12	small cell carcinoma of the bladder	10.6	SYP KRT7
13	endolymphatic sac tumor	10.6	KRT8 KRT7
14	auditory system benign neoplasm	10.6	SYP KRT7
15	pancreatic serous cystadenocarcinoma	10.6	SYP KRT7
16	plagiocephaly	10.6	FGFR2 FGFR1
17	vaginal tubulovillous adenoma	10.6	SYP KRT7
18	urinary bladder small cell neuroendocrine carcinoma	10.6	SYP KRT7
19	subareolar duct papillomatosis	10.6	KRT8 KRT7
20	ureter small cell carcinoma	10.6	SYP KRT7
21	nipple benign neoplasm	10.6	KRT8 KRT7
22	middle ear adenoma	10.6	SYP KRT7
23	benign breast adenomyoepithelioma	10.6	KRT8 KRT7
24	jejunal neoplasm	10.6	SYP KRT7
25	krukenberg carcinoma	10.6	SYP KRT7
26	rosette-forming glioneuronal tumor	10.6	SYP FGFR1
27	gallbladder small cell carcinoma	10.6	SYP KRT7
28	gastrointestinal neuroendocrine benign tumor	10.6	SYP GAST
29	sensory organ benign neoplasm	10.6	SYP KRT7
30	mixed ductal-endocrine carcinoma	10.6	SYP GAST
31	ovarian large-cell neuroendocrine carcinoma	10.6	SYP KRT7
32	appendix adenocarcinoma	10.6	SYP KRT7
33	mucinous ovarian cystadenoma	10.6	KRT7 GAST
34	primary hepatic neuroendocrine carcinoma	10.6	VIM SYP
35	glomangiomyoma	10.6	VIM SYP
36	nodular hidradenoma	10.6	VIM KRT7
37	papillary tumor of the pineal region	10.6	VIM SYP
38	rete testis neoplasm	10.6	KRT7 AFP
39	syndromic craniosynostosis	10.6	FGFR2 FGFR1
40	wolffian duct adenocarcinoma	10.6	KRT7 FGFR2
41	rete testis adenocarcinoma	10.6	KRT7 AFP
42	benign metastasizing leiomyoma	10.6	VIM KRT7
43	testicular spermatocytic seminoma	10.6	NR0B2 FGFR2
44	synovium neoplasm	10.6	KRT8 KRT7
45	ureteral benign neoplasm	10.6	SYP KRT7
46	pineal region teratoma	10.5	SYP AFP
47	gastric neuroendocrine neoplasm	10.5	SYP GAST
48	thymus sarcomatoid carcinoma	10.5	SYP AFP
49	ovarian endodermal sinus tumor	10.5	KRT7 AFP
50	epididymal neoplasm	10.5	KRT7 AFP

Graphical network of the top 20 diseases related to Fibrolamellar Carcinoma:

Sources

Symptoms & Phenotypes for Fibrolamellar Carcinoma

UMLS symptoms related to Fibrolamellar Carcinoma:

fever, abdominal pain, icterus, malaise

GenomeRNAi Phenotypes related to Fibrolamellar Carcinoma according to GeneCards Suite gene sharing:

²⁶

#	Description	GenomeRNAi Source Accession	Score	Top Affiliating Genes
1	Decreased shRNA abundance (Z-score < -2)	GR00366-A-114	9.28	AFP
2	Decreased shRNA abundance (Z-score < -2)	GR00366-A-120	9.28	AFP
3	Decreased shRNA abundance (Z-score < -2)	GR00366-A-29	9.28	AFP
4	Decreased shRNA abundance (Z-score < -2)	GR00366-A-6	9.28	KRT8
5	Decreased shRNA abundance (Z-score < -2)	GR00366-A-63	9.28	AFP
6	Decreased shRNA abundance (Z-score < -2)	GR00366-A-65	9.28	AFP
7	Decreased shRNA abundance (Z-score < -2)	GR00366-A-71	9.28	KRT7 KRT8
8	Decreased shRNA abundance (Z-score < -2)	GR00366-A-75	9.28	AFP

MGI Mouse Phenotypes related to Fibrolamellar Carcinoma:

⁴⁵

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	homeostasis/metabolism	MP:0005376	10.24	AFP CCKBR FGFR1 FGFR2 GAST ITGA1
2	cardiovascular system	MP:0005385	10.22	CCKBR FGFR1 FGFR2 ITGA1 ITGAV ITGB4
3	growth/size/body region	MP:0005378	10.18	CCKBR FGFR1 FGFR2 ITGA1 ITGAV ITGB4
4	digestive/alimentary	MP:0005381	10.16	CCKBR FGFR1 FGFR2 GAST ITGAV ITGB4
5	endocrine/exocrine gland	MP:0005379	10.13	AFP CCKBR FGFR1 FGFR2 GAST ITGAV
6	immune system	MP:0005387	10.06	CCKBR FGFR1 FGFR2 GAST ITGA1 ITGAV
7	liver/biliary system	MP:0005370	9.86	AFP CCKBR FGFR2 KRT19 KRT8 NR0B2
8	neoplasm	MP:0002006	9.7	AFP FGFR2 GAST ITGAV KRT19 PRKACA
9	nervous system	MP:0003631	9.7	CCKBR FGFR1 FGFR2 ITGAV ITGB4 KRT19
10	renal/urinary system	MP:0005367	9.28	CCKBR FGFR1 FGFR2 ITGA1 ITGAV ITGB4

Sources

Drugs & Therapeutics for Fibrolamellar Carcinoma

Drugs for Fibrolamellar Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 24)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Everolimus

Approved

Phase 2

159351-69-6

70789204 6442177

Synonyms:

(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.0(sup 4,9))hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone

(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.04,9)hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone

(1R,9S,12S,15R,16E,23S,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.0(sup 4,9))hexatriacont

(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34as)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-9,27-dihydroxy-3-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-10,21-dimethoxy-6,8,12,14,20,26-hexamethy

(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-Hexadecahydro-9,27-dihydroxy-3-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-23,27-epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone

(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,27-dihydroxy-3-{(2R)-1-[(1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl]propan-2-yl}-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-3H-23,27-epoxypyrido[2,1-c][1,4]oxazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone

001, RAD

07741_FLUKA

159351-69-6

40-O-(2-hydroxyethyl)-rapamycin

40-O-(2-Hydroxyethyl)-rapamycin

42-O-(2-Hydroxyethyl)rapamycin

Afinitor

Certican

CERTICAN(R)

CHEMBL1201755

D02714

DB01590

everolimus

Everolimus

évérolimus

Everolimus (JAN/USAN/INN)

Everolimus [USAN]

LS-143292

MolPort-003-847-342

MolPort-003-925-588

NCGC00167512-01

NVP-RAD-001

RAD 001

RAD, SDZ

RAD001

RAD-001

RAD001, SDZ-RAD, Certican, Zortress, Afinitor, Everolimus

RAD-001C

S1120_Selleck

SDZ RAD

SDZ-RAD

UNII-9HW64Q8G6G

Zortress

Letrozole

Approved, Investigational

Phase 2

112809-51-5

3902

Synonyms:

1-[bis(4-cyanophenyl)methyl]-1,2,4-triazole

1-[Bis-(4-cyanophenyl)methyl]-1,2,4-triazole

112809-51-5

4,4'-((1h-1,2,4-triazol-1-yl)methylene)dibenzonitrile

4,4'-(1H-1,2,4-triazol-1-ylmethanediyl)dibenzonitrile

4,4'-(1h-1,2,4-triazol-1-ylmethylene) bis-benzonitrile

4,4'-(1H-1,2,4-triazol-1-yl-methylene)-bis(benzonitrile)

4,4'-(1H-1,2,4-Triazol-1-yl-methylene)-bis(benzonitrile)

4,4'-(1h-1,2,4-triazol-1-ylmethylene)bisbenzonitrile

4,4'-(1h-1,2,4-triazol-1-ylmethylene)bis-benzonitrile

4,4'-(1H-1,2,4-triazol-1-ylmethylene)bis-Benzonitrile Letrozole

4,4'-(1H-1,2,4-Triazol-1-ylmethylene)dibenzonitrile

4-[(4-cyanophenyl)-(1,2,4-triazol-1-yl)methyl]benzonitrile

AB00514009

AC-1193

AC1L1GYT

AKOS005145822

BIDD:GT0015

BIDD:PXR0130

Bio-0057

BPBio1_001331

BRD-K88789588-001-03-2

BSPBio_001209

C067431

C08163

C17H11N5

CAS-112809-51-5

CCRIS 8822

CGS 20267

CGS 20267, Femara, Piroxicam, Letrozole

CGS-20267

CHEBI:6413

CHEMBL1444

CID3902

CPD000466343

D00964

DB01006

FEM-345

Femara

Fémara

Femara (TN)

Femera

HMS1571M11

HMS2051E08

HMS2089L22

HSDB 7461

I06-0022

Letoval

Letrozol

letrozole

Letrozole

Letrozole (JAN/USP/INN)

Letrozole [USAN:INN]

LS-38788

MLS000759455

MLS001424038

MLS002584991

MolPort-003-848-373

NCGC00016973-01

NCGC00016973-02

Novartis brand OF letrozole

Novartis Brand of Letrozole

NSC719345

Prestwick0_001025

Prestwick1_001025

Prestwick2_001025

Prestwick3_001025

S1235_Selleck

SAM001246649

SMR000466343

SPBio_003070

TL8000371

UNII-7LKK855W8I

ZINC03778874

Leuprolide

Approved, Investigational

Phase 2

53714-56-0

657181 3911

Synonyms:

(D-Leu(6),des-gly-NH2(10),pro-ethylamide(9))-gonadotropin-releasing hormone

5-oxoPro-His-Trp-Ser-Tyr-D-Leu-Leu-Arg-ProNHC2H5 dihydrate

5-oxoprolylhistidyltryptophylseryltyrosylleucylleucyl-n5-(diaminomethylidene)ornithyl-n-ethylprolinamide

AC1L1GZK

AC1L9B44

AC1Q5OPO

Acetate, leuprolide

acetic acid

AR-1G9354

C07612

CID3911

CID441410

D00989

D08113

Enantone

Enantone (TN)

I04-0109

L001094

L002030

leuprolide

Leuprolide

Leuprolide acetate

Leuprolide monoacetate

Leuprolide, (DL-leu)-isomer

Leuprolide, (L-leu)-isomer

Leuprorelin

Leuprorelin (INN)

Leuprorelin acetate

Leuprorelin acetate (JAN)

Leuprorelina

Leuproreline

Leuprorelinum

L-Pyroglutamyl-L-histidyl-L-tryptophyl-L-seryl-L-tyrosyl-D-leucyl-L-leucyl-L-arginyl-L-proline ethylamide

Lupron

Lupron (TN)

Monoacetate, leuprolide

N-[1-[[1-[[1-[[1-[[1-[[1-[[5-(diaminomethylideneamino)-1-[2-(ethylcarbamoyl)pyrrolidin-1-yl]-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]-5-oxopyrrolidine-2-carboxamide

NSC377526

NSC746847

PGlu-his-TRP-ser-tyr-D-leu-leu-arg-pro-NHC2H5

PGlu-his-TRP-ser-tyr-D-leu-leu-arg-pro-nhet

TAP 144

TAP-144

nivolumab

Approved

Phase 1, Phase 2

946414-94-4

Fluorouracil

Approved

Phase 1, Phase 2

51-21-8

3385

Synonyms:

1004-03-1

1-fluoro-1h-pyrimidine-2,4-dione

1upf

2,4-Dihydroxy-5-fluoropyrimidine

2,4-Dioxo-5-fluoropryimidine

2,4-Dioxo-5-fluoropyrimidine

47576_FLUKA

4921-97-5

5 Fluorouracil

5 Fluorouracil biosyn

5 FU lederle

5 FU Lederle

5 FU medac

5 HU hexal

5 HU Hexal

51-21-8

5-Faracil

5-Fluor-2,4(1H,3H)-pyrimidindion

5-Fluor-2,4(1H,3H)-pyrimidindion [Czech]

5-Fluor-2,4-dihydroxypyrimidin

5-Fluor-2,4-dihydroxypyrimidin [Czech]

5-Fluor-2,4-pyrimidindiol

5-Fluor-2,4-pyrimidindiol [Czech]

5-Fluoracil

5-Fluoracil [German]

5-Fluoracyl

5-fluoro uracil

5-fluoro-1H-pyrimidine-2,4-dione

5-Fluoro-2,4(1H,3H)-pyrimidinedione

5-Fluoro-2,4-pyrimidinedione

5-Fluoropyrimidin-2,4-diol

5-fluoropyrimidine-2,4(1H,3H)-dione

5-Fluoropyrimidine-2,4-dione

5-fluorouracil

5-Fluorouracil

5-Fluorouracil-biosyn

5-Fluoruracil

5-Fluoruracil [German]

5-Fluracil

5-Ftouracyl

5FU

5-FU

5-FU (TN)

5-FU lederle

5-FU Lederle

5-FU medac

5-HU hexal

5-HU Hexal

79108-01-3

AC-11201

AC1L1FTE

AC1Q4N2X

AccuSite

Actino-Hermal

Adrucil

Adrucil (TN)

AI3-25297

AKOS000119162

AKOS003237897

Allergan brand OF fluorouracil

Allergan Brand of Fluorouracil

Arumel

BB_NC-0576

biosyn Brand of Fluorouracil

Biosyn brand OF fluorouracil

BSPBio_002048

C07649

C4H3FN2O2

Carac

Carac (TN)

Carzonal

CCRIS 2582

CHEBI:46345

CHEMBL185

CID3385

Cinco FU

CPD000038082

CPD0-1327

CSP Brand of Fluorouracil

CSP Brand OF fluorouracil

Cytosafe

D005472

D00584

Dakota brand OF fluorouracil

Dakota Brand of Fluorouracil

Dakota, fluorouracile

Dakota, Fluorouracile

DB00544

Dermatech brand OF fluorouracil

Dermatech Brand of Fluorouracil

Dermik brand OF fluorouracil

Dermik Brand of Fluorouracil

DivK1c_000054

Effluderm

Effluderm (free base)

Efudex

Efudix

Efurix

EINECS 200-085-6

EU-0100536

F 6627

F0151

F6627_SIGMA

F8423_SIGMA

Ferrer brand OF fluorouracil

Ferrer Brand of Fluorouracil

Fiverocil

Fluoro Uracil

fluoro Uracile icn

Fluoro Uracile ICN

Fluoroblastin

Fluoroplex

Fluoroplex (TN)

fluorouracil

Fluorouracil

Fluorouracil (JP15/USP/INN)

Fluorouracil [USAN:INN:BAN:JAN]

Fluorouracil gry

Fluorouracil GRY

Fluorouracil mononitrate

Fluorouracil Mononitrate

Fluorouracil monopotassium salt

Fluorouracil Monopotassium Salt

Fluorouracil monosodium salt

Fluorouracil Monosodium Salt

Fluorouracil potassium salt

Fluorouracil Potassium Salt

Fluorouracil teva brand

Fluorouracil Teva Brand

Fluorouracile

Fluoro-uracile

Fluorouracile [DCIT]

Fluorouracile dakota

Fluorouracile Dakota

fluoro-Uracile icn

Fluoro-Uracile ICN

Fluorouracil-gry

Fluorouracil-GRY

Fluorouracilo

Fluoro-uracilo

Fluorouracilo [INN-Spanish]

fluorouracilo Ferrer far

Fluorouracilo Ferrer Far

Fluorouracilum

Fluorouracilum [INN-Latin]

Fluoruracil

Fluouracil

Flurablastin

Fluracedyl

Fluracil

Fluracilum

Fluri

Fluril

Fluro Uracil

Fluroblastin

Flurodex

Flurouracil

Flurox

FT-0082524

Ftoruracil

Gry brand OF fluorouracil

Gry Brand of Fluorouracil

haemato Brand OF fluorouracil

Haemato Brand of Fluorouracil

haemato Fu

Haemato fu

haemato-Fu

Haemato-fu

Hexal brand OF fluorouracil

Hexal Brand of Fluorouracil

HMS1920O18

HMS2090I04

HMS2091F19

HMS500C16

HSDB 3228

I07-0022

ICN brand OF fluorouracil

ICN Brand of Fluorouracil

IDI1_000054

IN1335

inhibits thymilidate synthetase

KBio1_000054

KBio2_001321

KBio2_003889

KBio2_006457

KBio3_001268

KBioGR_001253

KBioSS_001321

Kecimeton

Lopac0_000536

Lopac-F-6627

LS-153

medac Brand of Fluorouracil

Medac brand OF fluorouracil

MLS000069498

MLS002415705

MolPort-000-156-102

MolPort-003-990-447

MolPort-004-758-143

MolPort-004-758-144

MolPort-005-861-486

NCGC00015442-01

NCGC00015442-03

NCGC00015442-10

NCGC00091349-01

NCGC00091349-02

NCGC00091349-03

NCGC00091349-04

NCGC00091349-05

NCGC00091349-07

NCGC00091349-08

nchembio.90-comp3

nchembio809-comp6

NCI60_001652

Neocorp brand OF fluorouracil

Neocorp Brand of Fluorouracil

Neofluor

NINDS_000054

NSC 19893

NSC19893

NSC-19893

Onkofluor

Onkoworks brand OF fluorouracil

Onkoworks Brand of Fluorouracil

Pharmachemie brand OF fluorouracil monosodium salt

Phthoruracil

Phtoruracil

Queroplex

Ribofluor

ribosepharm Brand of Fluorouracil

Ribosepharm brand OF fluorouracil

Riemser brand OF fluorouracil

Riemser Brand of Fluorouracil

Ro 2-9757

Ro-2-9757

Roche brand OF fluorouracil

Roche Brand of Fluorouracil

S1209_Selleck

SAM002264615

SMR000038082

SPBio_000291

Spectrum_000841

SPECTRUM1500305

Spectrum2_000076

Spectrum3_000434

Spectrum4_000557

Spectrum5_000718

STK297802

T5233394

tetratogen

Teva brand OF fluorouracil

Teva Brand of Fluorouracil

Timazin

TL8006093

U 8953

U-8953

Ulup

UNII-U3P01618RT

UPCMLD-DP130

UPCMLD-DP130:001

URF

WLN: T6MVMVJ EF

ZINC00897110

Sunitinib

Approved, Investigational

Phase 2

557795-19-4, 341031-54-7

5329102

Synonyms:

(2S)-2-hydroxybutanedioic acid

1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-, (2S)-hydroxybutanedioate (1:1)

326914-13-0

341031-54-7

5-(5-FLUORO-2-OXO-1,2-DIHYDRO-INDOL-3-YLIDENEMETHYL)-2,4-DIMETHYL-1H-PYRROLE-3-CARBOXYLIC ACID (2-DIETHYLAMINO-ETHYL)-AMIDE

5-(5-fluoro-2-oxo-1,2-Dihydroindolylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide

557795-19-4

AC1NS62J

AC1O5CMQ

AKOS005145765

Butanedioic acid, hydroxy-, (2S)-, compd. with N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide (1:1)

CHEBI:38940

CHEBI:550864

CHEMBL1567

CHEMBL535

CID5329102

CID6456015

D06402

D08552

DB01268

DB07417

EN002687

FT-0083555

FT-0083556

I01-1229

K00588a

KS-5022

LS-186078

LS-187023

LS-187648

MolPort-003-986-763

N-(2-(Diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide (2S)-hydroxybutanedioate

N-(2-diethylaminoethyl)-5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide

N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide

NCGC00164631-01

NSC736511

NSC750690

PDGF TK antagonist

PHA-290940AD

PNU-290940AD

S1042_Selleck

ST51053712

SU 011248

SU 11248

SU010398

SU-010398

Su-011248

SU011248

SU011248 L-malate salt

SU-011248 L-malate salt

SU11248

SU-11248

SU-11248 L-malate salt

SU-11248J

SU-12662

Sunitanib

sunitinib

Sunitinib

Sunitinib (free base)

Sunitinib (INN)

Sunitinib malate

Sunitinib malate (JAN/USAN)

Sunitinib malate [USAN]

sunitinibum

Sunitinibum

Sutent

Sutent (TN)

Sutent, SU-11248

TL8002546

UNII-LVX8N1UT73

UNII-V99T50803M

Estrogen Antagonists

Phase 2

Estrogen Receptor Antagonists

Phase 2

Estrogens

Phase 2

Aromatase Inhibitors

Phase 2

interferons

Phase 1, Phase 2

Antineoplastic Agents, Immunological

Phase 1, Phase 2

Interferon alpha-2

Phase 1, Phase 2

Interferon-alpha

Phase 1, Phase 2

Antiviral Agents

Phase 1, Phase 2

Antimetabolites

Phase 1, Phase 2

Protein Kinase Inhibitors

Phase 2

Angiogenesis Inhibitors

Phase 2

Ipilimumab

Approved

Phase 1

477202-00-9

Immunoglobulins

Phase 1

Antibodies

Phase 1

Vaccines

Phase 1

Antibodies, Blocking

Phase 1

Poly ICLC

Phase 1

Interventional clinical trials:

#	Name	Status	NCT ID	Phase	Drugs
1	A Phase 2, Multi-center, Open-label Study of Oral ENMD-2076 for the Treatment of Patients With Advanced Fibrolamellar Carcinoma (FLC)	Completed	NCT02234986	Phase 2	ENMD-2076
2	A Randomized Three Arm Phase II Study of (1) Everolimus, (2) Estrogen Deprivation Therapy (EDT) With Leuprolide + Letrozole and (3) Everolimus + EDT in Patients With Unresectable Fibrolamellar Hepatocellular Carcinoma (FLL-HCC)	Active, not recruiting	NCT01642186	Phase 2	everolimus;letrozole plus leuprolide;combination of everolimus, letrozole and leuprolide
3	A Phase I/II Study of Nivolumab Plus 5-Fluorouracil Plus Interferon-α2b for Unresectable Fibrolamellar Hepatocellular Carcinoma	Not yet recruiting	NCT04380545	Phase 1, Phase 2	Fluorouracil
4	A Multicenter National Phase II Open Study Coupled With Translational Assessment of Biomarkers Predictive of Response to Sunitinib in Patients With Advanced/Inoperable Fibrolamellar Hepatocellular Carcinoma.	Terminated	NCT01215565	Phase 2	Sutent
5	Sequential, Related Donor Partial Liver Transplantation Followed by Bone Marrow Transplantation for Fibrolamellar or Non-fibrolamellar Hepatocellular Carcinoma (HCC) Including Fibrolamellar HCC	Withdrawn	NCT02702960	Phase 2	Cyclophosphamide;Mesna;Filgrastim;Tacrolimus;mycophenolate mofetil;Prednisone;Antithymocyte globulin;fludarabine
6	Phase II Study of Oral Vancomycin in Patients With Unresectable Fibrolamellar Hepatocellular Carcinoma (FLC)	Withdrawn	NCT04025567	Phase 2	vancomycin
7	A Pilot Study of a DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Fibrolamellar Hepatocellular Carcinoma	Recruiting	NCT04248569	Phase 1	DNAJB1-PRKACA peptide vaccine;Nivolumab;Ipilimumab
8	A Natural History Study of Children and Adults With Fibrolamellar Hepatocellular Carcinoma	Withdrawn	NCT03748927
9	Molecular Analysis of Liver Cancer	Withdrawn	NCT00899002

Search NIH Clinical Center for Fibrolamellar Carcinoma

Cochrane evidence based reviews: fibrolamellar hepatocellular carcinoma

Sources

Genetic Tests for Fibrolamellar Carcinoma

Sources

Anatomical Context for Fibrolamellar Carcinoma

MalaCards organs/tissues related to Fibrolamellar Carcinoma:

⁴⁰

Liver, Lymph Node, Bone Marrow, Bone, Lung, Testes, Pancreas

Sources

Publications for Fibrolamellar Carcinoma

Articles related to Fibrolamellar Carcinoma:

(show top 50) (show all 467)

#	Title	Authors	PMID	Year
1	ASO Author Reflections: Fibrolamellar Hepatocellular Carcinoma and Alpha-Fetoprotein. ⁶¹	McDonald JD...Hernandez JM	32189170	2020
2	Fibrolamellar Carcinoma With Predominantly Pseudoglandular Architecture: A Potential Diagnostic Pitfall. ⁶¹	du Toit M...Aldera AP	32508199	2020
3	Fibrolamellar Carcinoma. ⁶¹	Erickson LA	32498783	2020
4	Fibrolamellar Carcinoma: Novel Insights into a Rare Subtype. ⁶¹	Patel A...Somasundar P	32056041	2020
5	Elevated Serum α-Fetoprotein is Associated with Abbreviated Survival for Patients with Fibrolamellar Hepatocellular Carcinoma Who Undergo a Curative Resection. ⁶¹	McDonald JD...Hernandez JM	31925595	2020
6	A Multicenter Randomized Three-Arm Phase II Study of (1) Everolimus, (2) Estrogen Deprivation Therapy (EDT) with Leuprolide + Letrozole, and (3) Everolimus + EDT in Patients with Unresectable Fibrolamellar Carcinoma. ⁶¹	El Dika I...Abou-Alfa GK	32400000	2020
7	In situ hybridisation for albumin RNA in paediatric liver cancers compared with common immunohistochemical markers. ⁶¹	Chen DA...Lagana SM	32471888	2020
8	Clinical features and surgical outcomes of fibrolamellar hepatocellular carcinoma: retrospective analysis of a single-center experience. ⁶¹	Lemekhova A...Hoffmann K	32397993	2020
9	BAP1 mutations define a homogeneous subgroup of hepatocellular carcinoma with fibrolamellar-like features and activated PKA. ⁶¹	Hirsch TZ...Zucman-Rossi J	31862487	2020
10	Fibrolamellar hepatocellular carcinoma-related hyperammonemic encephalopathy: Up to now and next steps. ⁶¹	Surjan RCT...Machado MAC	31679315	2020
11	Hotspots of Aberrant Enhancer Activity in Fibrolamellar Carcinoma Reveal Candidate Oncogenic Pathways and Therapeutic Vulnerabilities. ⁶¹	Dinh TA...Sethupathy P	32294439	2020
12	DnaJ-PKAc fusion induces liver inflammation in a zebrafish model of fibrolamellar carcinoma. ⁶¹	de Oliveira S...Huttenlocher A	32102783	2020
13	DNAJB1-PRKACA fusions occur in oncocytic pancreatic and biliary neoplasms and are not specific for fibrolamellar hepatocellular carcinoma. ⁶¹	Vyas M...Basturk O	31676785	2020
14	Acute Onset Hyperammonemic Encephalopathy Related to Fibrolamellar Carcinoma: Another One Bites the Dust. ⁶¹	Surjan RCT...Soares SRP	32014302	2020
15	Phase II Multicenter, Open-Label Study of Oral ENMD-2076 for the Treatment of Patients with Advanced Fibrolamellar Carcinoma. ⁶¹	Abou-Alfa GK...Gordan JD	32154962	2020
16	Cytoreductive Surgery and HIPEC for Recurrent Fibrolamellar Hepatocellular Carcinoma with Peritoneal Carcinomatosis. ⁶¹	Kyziridis D...Tentes AK	30989576	2020
17	Imaging Features of Fibrolamellar Hepatocellular Carcinoma with Contrast-Enhanced Ultrasound. ⁶¹	Dong Y...Dietrich CF	32102105	2020
18	Using dual checkpoint blockade to treat fibrolamellar hepatocellular carcinoma. ⁶¹	De Toni EN...Roessler D	32051207	2020
19	Fibrolamellar Hepatocellular Carcinoma: A Population-Based Observational Study. ⁶¹	Ramai D...Adler DG	32052215	2020
20	DNAJB1-PRKACA-positive metastatic fibrolamellar carcinoma with unknown primary in a pediatric patient. ⁶¹	Balbeur S...Brichard B	31736218	2020
21	Predictors of Outcome in Patients With Fibrolamellar Carcinoma: Analysis of the National Cancer Database. ⁶¹	Assi HA...Hatoum H	32014928	2020
22	Single-Cell RNA Sequencing Identifies Yes-Associated Protein 1-Dependent Hepatic Mesothelial Progenitors in Fibrolamellar Carcinoma. ⁶¹	Jewell ML...Diehl AME	31669305	2020
23	Clavicle tumor as an initial manifestation of fibrolamellar hepatocellular carcinoma. ⁶¹	Cebrian A...Ruiz-Clavijo D	31677896	2020
24	Hyperammonemic encephalopathy: An unusual presentation of fibrolamellar hepatocellular carcinoma. ⁶¹	Thakral N...Simonetto DA	31422648	2020
25	Fibrolamellar hepatocellular carcinoma with paraneoplastic neuropsychiatric manifestations. ⁶¹	Karam C...Das A	31965677	2020
26	MDM4 expression in fibrolamellar hepatocellular carcinoma. ⁶¹	Karki A...Vakili K	31322272	2019
27	Emerging Roles of GLI-Similar Krüppel-like Zinc Finger Transcription Factors in Leukemia and Other Cancers. ⁶¹	Jetten AM	31474360	2019
28	Inhibition of the chimeric DnaJ-PKAc enzyme by endogenous inhibitor proteins. ⁶¹	Averill AM...Ramsey JE	30938854	2019
29	A prognostic nomogram for patients with resected fibrolamellar hepatocellular carcinoma. ⁶¹	Lafaro KJ...Melstrom LG	31489303	2019
30	Neurotensin as a source of cyclic AMP and co-mitogen in fibrolamellar hepatocellular carcinoma. ⁶¹	Riehle KJ...Yeung RS	31489118	2019
31	Hepatocellular Carcinoma of Fibrolamellar Type in an Adolescent: Case Report and Literature Review. ⁶¹	Santiago-Reynoso J...Maldonado-Vega M	31602376	2019
32	Hyperammonemic encephalopathy in a patient with fibrolamellar hepatocellular carcinoma: case report and literature review. ⁶¹	Cho J...Halfdanarson TR	31183212	2019
33	Clinicopathological features and outcomes of fibrolamellar hepatocellular carcinoma. ⁶¹	Chakrabarti S...Mahipal A	31183207	2019
34	Spontaneous Rupture of Fibrolamellar Variant Hepatocellular Carcinoma. ⁶¹	Polavarapu AD...Sokoloff A	31236158	2019
35	Multiple Immune-Suppressive Mechanisms in Fibrolamellar Carcinoma. ⁶¹	Kim AK...Anders RA	30902819	2019
36	An acquired scaffolding function of the DNAJ-PKAc fusion contributes to oncogenic signaling in fibrolamellar carcinoma. ⁶¹	Turnham RE...Scott JD	31063128	2019
37	Structures of the PKA RIα Holoenzyme with the FLHCC Driver J-PKAcα or Wild-Type PKAcα. ⁶¹	Cao B...Zhang P	30905674	2019
38	Progression after Immunotherapy for Fibrolamellar Carcinoma. ⁶¹	Bauer U...Ehmer U	31312648	2019
39	Update on the pathology of liver neoplasms. ⁶¹	Matsukuma KE...Yeh MM	30597357	2019
40	[Hepatocellular carcinomas and their mimics]. ⁶¹	Fischer HP...Goltz D	30706100	2019
41	MicroRNA-375 Suppresses the Growth and Invasion of Fibrolamellar Carcinoma. ⁶¹	Dinh TA...Sethupathy P	30763770	2019
42	Road map for fibrolamellar carcinoma: progress and goals of a diversified approach. ⁶¹	Kastenhuber ER...Abou-Alfa GK	30951568	2019
43	Hardened Liver Due to Fibrolamellar Hepatocellular Carcinoma. ⁶¹	Luther J...Dienstag JL	29505903	2019
44	State-of-the-art MR Imaging of Uncommon Hepatocellular Tumours: Fibrolamellar Hepatocellular Carcinoma and Combined Hepatocellularcholangiocarcinoma. ⁶¹	Anysz-Grodzicka A...Cieszanowski A	31989878	2019
45	Fibrolamellar Hepatocellular Carcinoma with Multiple Lung Metastases Treated with Multidisciplinary Therapy. ⁶¹	Tanaka H...Hara K	30101933	2018
46	Acquired ornithine transcarbamylase deficiency in pediatric and adolescent patients with fibrolamellar hepatocellular carcinoma. ⁶¹	Bartlett AL...Geller JI	30094907	2018
47	Hepatic Sclerosing Hemangioma Simulating Gallbladder Carcinoma: A Rare Case. ⁶¹	Navale P...Fiel MI	30564006	2018
48	Fibrolamellar hepatocellular carcinoma: multiphasic CT features of the primary tumor on pre-therapy CT and pattern of distant metastases. ⁶¹	Ganeshan D...Elsayes KM	29948061	2018
49	Fibrolamellar carcinoma in the Carney complex: PRKAR1A loss instead of the classic DNAJB1-PRKACA fusion. ⁶¹	Graham RP...Torbenson MS	29222914	2018
50	Management of fibrolamellar hepatocellular carcinoma. ⁶¹	Chaudhari VA...Shrikhande SV	30395718	2018

Sources

Genes for Fibrolamellar Carcinoma

Genes related to Fibrolamellar Carcinoma (2 elite genes):

(show all 29)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence
1	PRKACA	Protein Kinase CAMP-Activated Catalytic Subunit Alpha	Protein Coding	372.64	Gene fusion ⁵⁸ DISEASES inferred ¹⁵ GeneCards inferred via : Publications Summaries (show sections)
2	DNAJB1	DnaJ Heat Shock Protein Family (Hsp40) Member B1	Protein Coding	364.63	Gene fusion ⁵⁸ DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
3	KRT7	Keratin 7	Protein Coding	12.93	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
4	FGFR1	Fibroblast Growth Factor Receptor 1	Protein Coding	10.78	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
5	NR0B2	Nuclear Receptor Subfamily 0 Group B Member 2	Protein Coding	10.48	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
6	SYP	Synaptophysin	Protein Coding	10.46	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
7	FGFR2	Fibroblast Growth Factor Receptor 2	Protein Coding	10.42	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
8	MIR375	MicroRNA 375	RNA Gene	10.28	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
9	YAP1	Yes1 Associated Transcriptional Regulator	Protein Coding	10.14	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
10	KRT8	Keratin 8	Protein Coding	10.01	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
11	CCKBR	Cholecystokinin B Receptor	Protein Coding	9.67	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
12	GAST	Gastrin	Protein Coding	9.58	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
13	AFP	Alpha Fetoprotein	Protein Coding	7.24	DISEASES inferred ¹⁵
14	NTS	Neurotensin	Protein Coding	6.56	DISEASES inferred ¹⁵
15	LINC00473	Long Intergenic Non-Protein Coding RNA 473	RNA Gene	6.56	DISEASES inferred ¹⁵
16	ITGA1	Integrin Subunit Alpha 1	Protein Coding	6.12	GeneCards inferred via : Publications (show sections)
17	ITGAV	Integrin Subunit Alpha V	Protein Coding	6.12	GeneCards inferred via : Publications (show sections)
18	ITGB4	Integrin Subunit Beta 4	Protein Coding	6.12	GeneCards inferred via : Publications (show sections)
19	VIM	Vimentin	Protein Coding	6.12	GeneCards inferred via : Publications (show sections)
20	KRT19	Keratin 19	Protein Coding	6.07	DISEASES inferred ¹⁵
21	GPC3	Glypican 3	Protein Coding	6.01	DISEASES inferred ¹⁵
22	LINC01307	Long Intergenic Non-Protein Coding RNA 1307	RNA Gene	6	DISEASES inferred ¹⁵
23	PRKAR2B	Protein Kinase CAMP-Dependent Type II Regulatory Subunit Beta	Protein Coding	5.89	DISEASES inferred ¹⁵
24	C11orf95	Chromosome 11 Open Reading Frame 95	Protein Coding	5.74	DISEASES inferred ¹⁵
25	TCN1	Transcobalamin 1	Protein Coding	5.62	DISEASES inferred ¹⁵
26	CD68	CD68 Molecule	Protein Coding	5.62	DISEASES inferred ¹⁵
27	CTNNB1	Catenin Beta 1	Protein Coding	5.61	DISEASES inferred ¹⁵
28	GLUL	Glutamate-Ammonia Ligase	Protein Coding	5.57	DISEASES inferred ¹⁵
29	C7orf50	Chromosome 7 Open Reading Frame 50	Protein Coding	5.53	DISEASES inferred ¹⁵

Sources

Variations for Fibrolamellar Carcinoma

Cosmic variations for Fibrolamellar Carcinoma:

⁹ (show top 50) (show all 15431)

#	Cosmic Mut ID	Gene Symbol	COSMIC Disease Classification (Primary site, Site subtype, Primary histology, Histology subtype)	Mutation CDS	Mutation AA	GRCh38 Location	Conf
1	COSM97724722	ZXDB	liver,NS,carcinoma,hepatocellular carcinoma	c.1308C>A	p.D436E	23:57593356-57593356	6
2	COSM94436083	ZSWIM1	liver,NS,carcinoma,hepatocellular carcinoma	c.1399A>C	p.S467R	20:45883991-45883991	6
3	COSM94063771	ZSCAN20	liver,NS,carcinoma,hepatocellular carcinoma	c.2314G>T	p.G772W	1:33494658-33494658	6
4	COSM88264637	ZRSR2	liver,NS,carcinoma,hepatocellular carcinoma	c.304G>T	p.E102*	23:15803788-15803788	6
5	COSM131494492	ZNRF3	liver,NS,carcinoma,hepatocellular carcinoma	c.1159A>G	p.M387V	22:29049340-29049340	6
6	COSM102131817	ZNFX1	liver,NS,carcinoma,hepatocellular carcinoma	c.2580G>A	p.L860=	20:49257501-49257501	6
7	COSM113317148	ZNF853	liver,NS,carcinoma,hepatocellular carcinoma	c.1610G>T	p.G537V	7:6622601-6622601	6
8	COSM128686611	ZNF829	liver,NS,carcinoma,hepatocellular carcinoma	c.1072T>A	p.F358I	19:36891962-36891962	6
9	COSM123949383	ZNF827	liver,NS,carcinoma,hepatocellular carcinoma	c.1741C>T	p.L581=	4:145885684-145885684	6
10	COSM86004822	ZNF653	liver,NS,carcinoma,hepatocellular carcinoma	c.1553A>C	p.H518P	19:11485673-11485673	6
11	COSM139729931	ZNF615	liver,NS,carcinoma,hepatocellular carcinoma	c.141G>A	p.V47=	19:52002156-52002156	6
12	COSM91868668	ZNF536	liver,NS,carcinoma,hepatocellular carcinoma	c.3900G>T	p.K1300N	19:30557161-30557161	6
13	COSM91880764	ZNF536	liver,NS,carcinoma,hepatocellular carcinoma	c.2171-78T>G	p.?	19:30534769-30534769	6
14	COSM94799980	ZNF521	liver,NS,carcinoma,hepatocellular carcinoma	c.3658+205G>A	p.?	18:25194955-25194955	6
15	COSM90582798	ZNF518B	liver,NS,carcinoma,hepatocellular carcinoma	c.1624G>T	p.E542*	4:10444705-10444705	6
16	COSM87577038	ZNF462	liver,NS,carcinoma,hepatocellular carcinoma	c.6715G>T	p.V2239L	9:106974156-106974156	6
17	COSM151538615	ZNF385B	liver,NS,carcinoma,hepatocellular carcinoma	c.253+23785G>T	p.?	2:179745718-179745718	6
18	COSM111609487	ZNF276	liver,NS,carcinoma,hepatocellular carcinoma	c.1444C>G	p.L482V	16:89734008-89734008	6
19	COSM92353291	ZNF26	liver,NS,carcinoma,hepatocellular carcinoma	c.1010C>T	p.T337I	12:133010889-133010889	6
20	COSM95253159	ZNF217	liver,NS,carcinoma,hepatocellular carcinoma	c.*194A>T	p.?	20:53569094-53569094	6
21	COSM94505616	ZMYND12	liver,NS,carcinoma,hepatocellular carcinoma	c.425-1G>T	p.?	1:42440026-42440026	6
22	COSM89943752	ZMYM4	liver,NS,carcinoma,hepatocellular carcinoma	c.86-8201G>T	p.?	1:35350724-35350724	6
23	COSM101398456	ZIC2	liver,NS,carcinoma,hepatocellular carcinoma	c.-18C>T	p.?	13:99982047-99982047	6
24	COSM92703312	ZGPAT	liver,NS,carcinoma,hepatocellular carcinoma	c.*197C>A	p.?	20:63736116-63736116	6
25	COSM92032561	ZFYVE26	liver,NS,carcinoma,hepatocellular carcinoma	c.663C>A	p.A221=	14:67807621-67807621	6
26	COSM84360265	ZFR	liver,NS,carcinoma,hepatocellular carcinoma	c.1979+14C>A	p.?	5:32395145-32395145	6
27	COSM84362097	ZFR	liver,NS,carcinoma,hepatocellular carcinoma	c.2882C>T	p.P961L	5:32364229-32364229	6
28	COSM85178149	ZFP36L2	liver,NS,carcinoma,hepatocellular carcinoma	c.910T>G	p.S304A	2:43224894-43224894	6
29	COSM87884183	ZFP28	liver,NS,carcinoma,hepatocellular carcinoma	c.1865G>A	p.C622Y	19:56554650-56554650	6
30	COSM127392053	ZFHX4	liver,NS,carcinoma,hepatocellular carcinoma	c.10601C>G	p.S3534C	8:76864315-76864315	6
31	COSM149268658	ZFHX3	liver,NS,carcinoma,hepatocellular carcinoma	c.9997C>T	p.Q3333*	16:72788279-72788279	6
32	COSM149328017	ZFHX3	liver,NS,carcinoma,hepatocellular carcinoma	c.10852C>A	p.P3618T	16:72787424-72787424	6
33	COSM149281099	ZFHX3	liver,NS,carcinoma,hepatocellular carcinoma	c.8342A>G	p.Q2781R	16:72794340-72794340	6
34	COSM144309108	ZEB2	liver,NS,carcinoma,hepatocellular carcinoma	c.1141A>G	p.M381V	2:144400046-144400046	6
35	COSM87420403	ZCCHC14	liver,NS,carcinoma,hepatocellular carcinoma	c.71A>T	p.Q24L	16:87491757-87491757	6
36	COSM98996636	ZC3H7A	liver,NS,carcinoma,hepatocellular carcinoma	c.2866A>G	p.N956D	16:11751367-11751367	6
37	COSM92255466	ZC3H15	liver,NS,carcinoma,hepatocellular carcinoma	c.*55T>G	p.?	2:186508788-186508788	6
38	COSM85044193	ZC3H14	liver,NS,carcinoma,hepatocellular carcinoma	c.*10873G>A	p.?	14:88622624-88622624	6
39	COSM106743522	ZBTB7B	liver,NS,carcinoma,hepatocellular carcinoma	c.*635G>C	p.?	1:155017320-155017320	6
40	COSM93795261	ZBTB41	liver,NS,carcinoma,hepatocellular carcinoma	c.1700G>A	p.R567K	1:197178489-197178489	6
41	COSM103188148	ZBTB40	liver,NS,carcinoma,hepatocellular carcinoma	c.3339C>A	p.F1113L	1:22524258-22524258	6
42	COSM91488114	ZBTB4	liver,NS,carcinoma,hepatocellular carcinoma	c.454G>T	p.G152C	17:7466348-7466348	6
43	COSM95291738	ZBTB37	liver,NS,carcinoma,hepatocellular carcinoma	c.620G>C	p.S207T	1:173870845-173870845	6
44	COSM107993551	ZBTB10	liver,NS,carcinoma,hepatocellular carcinoma	c.2383A>G	p.I795V	8:80519295-80519295	6
45	COSM107993152	ZBTB10	liver,NS,carcinoma,hepatocellular carcinoma	c.2208A>G	p.T736=	8:80518852-80518852	6
46	COSM86073785	ZBED4	liver,NS,carcinoma,hepatocellular carcinoma	c.2225A>C	p.E742A	22:49885887-49885887	6
47	COSM142300159	YTHDF3	liver,NS,carcinoma,hepatocellular carcinoma	c.1580A>G	p.N527S	8:63187582-63187582	6
48	COSM90849676	YOD1	liver,NS,carcinoma,hepatocellular carcinoma	c.*157T>C	p.?	1:207048863-207048863	6
49	COSM90620829	YME1L1	liver,NS,carcinoma,hepatocellular carcinoma	c.2006A>G	p.H669R	10:27116230-27116230	6
50	COSM86902201	YEATS2	liver,NS,carcinoma,hepatocellular carcinoma	c.501C>T	p.N167=	3:183722100-183722100	6

Sources

Expression for Fibrolamellar Carcinoma

Search GEO for disease gene expression data for Fibrolamellar Carcinoma.

Sources

Pathways for Fibrolamellar Carcinoma

Pathways related to Fibrolamellar Carcinoma according to GeneCards Suite gene sharing:

(show all 18)

#	Super pathways	Score	Top Affiliating Genes
1	Developmental Biology ⁶⁵ Show member pathways Axon guidance ⁶⁵	13.34	PRKACA KRT8 KRT7 KRT19 ITGAV ITGA1
2	PI3K-Akt signaling pathway ³⁶ Show member pathways Human papillomavirus infection ³⁶	12.81	PRKACA ITGB4 ITGAV ITGA1 FGFR2 FGFR1
3	Actin Nucleation by ARP-WASP Complex ⁶³ Show member pathways Actin Nucleation and Branching ⁶³ CDC42 Pathway ⁶³ RhoA Pathway ⁶³	12.79	ITGB4 ITGAV ITGA1 FGFR2 FGFR1
4	NFAT and Cardiac Hypertrophy ⁶³ Show member pathways IGF1R Signaling ⁶³ Signaling Involved in Cardiac Hypertrophy ⁶³	12.62	PRKACA ITGB4 ITGAV ITGA1 FGFR2 FGFR1
5	Regulation of actin cytoskeleton ³⁶ ¹	12.42	ITGB4 ITGAV ITGA1 FGFR2 FGFR1
6	Cytoskeletal Signaling ⁴	12.25	VIM KRT8 KRT7 KRT19 ITGAV
7	G-protein signaling RAC1 in cellular process ²² Show member pathways CDC42 signaling events ¹ Cytoskeleton remodeling CDC42 in cellular processes ²² RAC1 signaling pathway ¹	12.23	ITGB4 ITGAV ITGA1 FGFR2 FGFR1
8	Dilated cardiomyopathy (DCM) ³⁶ Show member pathways Hypertrophic cardiomyopathy (HCM) ³⁶	12.08	PRKACA ITGB4 ITGAV ITGA1
9	Angiogenesis (CST) ⁴	11.7	ITGAV FGFR2 FGFR1
10	Phagocytosis of Microbes ⁶³	11.67	ITGB4 ITGAV ITGA1
11	Neural Stem Cells and Lineage-specific Markers ⁶⁴	11.62	VIM SYP FGFR1
12	MAPK Signaling: Mitogens ⁶⁴ Show member pathways Akt Signaling Pathway ⁶⁴	11.62	YAP1 ITGB4 ITGAV ITGA1 FGFR2 FGFR1
13	Cytoskeleton remodeling Neurofilaments ²² Show member pathways Cytoskeleton remodeling Keratin filaments ²²	11.59	VIM KRT8 KRT7 KRT19
14	Primary Focal Segmental Glomerulosclerosis FSGS ¹	11.33	VIM KRT8 ITGB4 ITGAV
15	Cell adhesion_Endothelial cell contacts by non-junctional mechanisms ²²	11.21	ITGB4 ITGAV ITGA1
16	G-protein signaling_RhoA regulation pathway ²²	10.79	PRKACA ITGB4 ITGAV ITGA1 FGFR2 FGFR1
17	G-protein signaling_Rap2B regulation pathway ²²	10.7	VIM ITGB4 ITGAV ITGA1 FGFR2 FGFR1
18	Secretion of Hydrochloric Acid in Parietal Cells ¹	10.18	GAST CCKBR

Sources

GO Terms for Fibrolamellar Carcinoma

Cellular components related to Fibrolamellar Carcinoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	extracellular exosome	GO:0070062	9.61	VIM PRKACA KRT8 KRT7 KRT19 ITGB4
2	intermediate filament	GO:0005882	9.46	VIM KRT8 KRT7 KRT19
3	integrin complex	GO:0008305	8.8	ITGB4 ITGAV ITGA1

Biological processes related to Fibrolamellar Carcinoma according to GeneCards Suite gene sharing:

(show all 17)

#	Name	GO ID	Score	Top Affiliating Genes
1	viral process	GO:0016032	9.93	VIM KRT8 KRT7 KRT19 ITGAV
2	positive regulation of cell proliferation	GO:0008284	9.92	YAP1 ITGAV FGFR2 FGFR1 CCKBR
3	integrin-mediated signaling pathway	GO:0007229	9.73	ITGB4 ITGAV ITGA1
4	cell-matrix adhesion	GO:0007160	9.72	ITGB4 ITGAV ITGA1
5	regulation of osteoblast differentiation	GO:0045667	9.57	PRKACA FGFR2
6	mesodermal cell differentiation	GO:0048333	9.51	ITGB4 FGFR2
7	branching involved in salivary gland morphogenesis	GO:0060445	9.49	FGFR2 FGFR1
8	mesenchymal cell differentiation	GO:0048762	9.48	FGFR2 FGFR1
9	lung-associated mesenchyme development	GO:0060484	9.46	FGFR2 FGFR1
10	paraxial mesoderm development	GO:0048339	9.43	YAP1 FGFR1
11	positive regulation of phospholipase activity	GO:0010518	9.4	FGFR2 FGFR1
12	bud elongation involved in lung branching	GO:0060449	9.37	YAP1 FGFR2
13	positive regulation of cardiac muscle cell proliferation	GO:0060045	9.33	YAP1 FGFR2 FGFR1
14	cell differentiation involved in embryonic placenta development	GO:0060706	9.32	KRT8 KRT19
15	orbitofrontal cortex development	GO:0021769	9.26	FGFR2 FGFR1
16	ventricular zone neuroblast division	GO:0021847	8.96	FGFR2 FGFR1
17	fibroblast growth factor receptor signaling pathway involved in orbitofrontal cortex development	GO:0035607	8.62	FGFR2 FGFR1

Molecular functions related to Fibrolamellar Carcinoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	protein binding	GO:0005515	10.21	YAP1 VIM PRKACA NTS NR0B2 LINC00473
2	insulin-like growth factor I binding	GO:0031994	9.32	ITGB4 ITGAV
3	neuregulin binding	GO:0038132	9.16	ITGB4 ITGAV
4	fibroblast growth factor-activated receptor activity	GO:0005007	8.96	FGFR2 FGFR1
5	fibroblast growth factor binding	GO:0017134	8.8	ITGAV FGFR2 FGFR1

Sources

Sources for Fibrolamellar Carcinoma

¹ BioSystems

² BitterDB

³ CDC

⁴ Cell Signaling Technology

⁵ ClinicalTrials

⁶ ClinVar

⁷ CNVD

⁸ Cochrane Library

⁹ Cosmic

¹⁰ dbSNP

¹¹ DGIdb

¹² Disease Ontology

¹³ diseasecard

¹⁴ DiseaseEnhancer

¹⁵ DISEASES

¹⁶ DrugBank

¹⁷ EFO

¹⁸ ExPASy

¹⁹ FMA

²⁰ GeneAnalytics

²¹ GeneCards

²² GeneGo (Thomson Reuters)

²³ GeneHancer via GeneCards

²⁴ GeneReviews

²⁵ Genetics Home Reference

²⁶ GenomeRNAi

²⁷ GEO DataSets

²⁸ GO

²⁹ GTR

³⁰ HMDB

³¹ HPO

³² ICD10

³³ ICD10 via Orphanet

³⁴ ICD9CM

³⁵ IUPHAR

³⁶ KEGG

³⁷ LifeMap

³⁸ LncRNADisease

³⁹ LOVD

⁴⁰ MalaCards

⁴¹ MedGen

⁴² MedlinePlus

⁴³ MeSH

⁴⁴ MESH via Orphanet

⁴⁵ MGI

⁴⁶ miR2Disease

⁴⁷ NCBI Bookshelf

⁴⁸ NCI

⁴⁹ NCIt

⁵⁰ NDF-RT

⁵¹ NIH Clinical Center

⁵² NIH Rare Diseases

⁵³ NINDS

⁵⁴ Novoseek

⁵⁵ Novus Biologicals

⁵⁶ OMIM

⁵⁷ OMIM via Orphanet

⁵⁸ Orphanet

⁵⁹ PathCards

⁶⁰ PharmGKB

⁶¹ PubMed

⁶² PubMed Health

⁶³ QIAGEN

⁶⁴ R&D Systems

⁶⁵ Reactome

⁶⁶ Sino Biological

⁶⁷ SNOMED-CT

⁶⁸ SNOMED-CT via HPO

⁶⁹ TGDB

⁷⁰ Tocris

⁷¹ UMLS

⁷² UMLS via Orphanet

⁷³ UniProtKB/Swiss-Prot

⁷⁴ Wikipedia

Fibrolamellar Carcinoma (FHCC)

Aliases & Classifications for Fibrolamellar Carcinoma

MalaCards integrated aliases for Fibrolamellar Carcinoma:

Characteristics:

Orphanet epidemiological data:

Classifications:

External Ids:

Summaries for Fibrolamellar Carcinoma

Related Diseases for Fibrolamellar Carcinoma

Diseases related to Fibrolamellar Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

Graphical network of the top 20 diseases related to Fibrolamellar Carcinoma:

Symptoms & Phenotypes for Fibrolamellar Carcinoma

UMLS symptoms related to Fibrolamellar Carcinoma:

GenomeRNAi Phenotypes related to Fibrolamellar Carcinoma according to GeneCards Suite gene sharing:

MGI Mouse Phenotypes related to Fibrolamellar Carcinoma:

Drugs & Therapeutics for Fibrolamellar Carcinoma

Drugs for Fibrolamellar Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

Interventional clinical trials:

Cochrane evidence based reviews: fibrolamellar hepatocellular carcinoma

Genetic Tests for Fibrolamellar Carcinoma

Anatomical Context for Fibrolamellar Carcinoma

MalaCards organs/tissues related to Fibrolamellar Carcinoma:

Publications for Fibrolamellar Carcinoma

Articles related to Fibrolamellar Carcinoma:

Genes for Fibrolamellar Carcinoma

Genes related to Fibrolamellar Carcinoma (2 elite genes):

Variations for Fibrolamellar Carcinoma

Cosmic variations for Fibrolamellar Carcinoma:

Expression for Fibrolamellar Carcinoma

Pathways for Fibrolamellar Carcinoma

Pathways related to Fibrolamellar Carcinoma according to GeneCards Suite gene sharing:

GO Terms for Fibrolamellar Carcinoma

Cellular components related to Fibrolamellar Carcinoma according to GeneCards Suite gene sharing:

Biological processes related to Fibrolamellar Carcinoma according to GeneCards Suite gene sharing:

Molecular functions related to Fibrolamellar Carcinoma according to GeneCards Suite gene sharing:

Sources for Fibrolamellar Carcinoma